- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 17:46 | AstraZeneca, Daiichi drug extends survival in hard-to-treat breast cancer | ||
| 16:46 | Skye shares crash as obesity drug falls short in key study | ||
| 13:46 | Chiesi buys into Arbor gene editing drug for rare kidney disease | ||
| 12:46 | The advantage of engaging patient recruitment partners as strategic allies, not emergency backups | ||
| 12:46 | Immune reset: How T cell engagers can change the autoimmune treatment landscape | ||
| Fr | AI could transform healthcare. Can safety-net providers keep up? | ||
| Fr | FDA clears generic abortion pill; CMS punts 'combo drug' guidance | ||
| Do | Amgen claims 'landmark' study result that could widen heart drug's use | ||
| Do | Galapagos to decide on fate of cell therapy business 'within weeks' | ||
| Do | Cartography secures $67M in pursuit of 'differentiated' cancer drugs | ||
| Mi | Takeda, in reversal, abandons cell therapy research | ||
| Mi | The top biopharma conferences in 2026 | ||
| Mi | A new biotech aims to get RNA drugs into the brain | ||
| Mi | As shutdown begins, FDA to stop accepting new drug submissions | ||
| Mi | FDA official's comments spark Aurinia sell-off; Halozyme buys a biotech | ||
| Di | Trump, Pfizer drug pricing deal short on details, possible impact | ||
| Di | Metsera strengthens case for Pfizer buyout with latest study data | ||
| Di | Crystalys debuts with $205M and plans for a better gout drug | ||
| Di | Star raises another $125M for its blood disease drug | ||
| 29.09. | Emma Walmsley, big pharma's first female CEO, to depart GSK | ||
| 29.09. | Genmab to acquire closely watched cancer drug in $8B Merus buyout | ||
| 29.09. | Moonlake shares crash on mixed study results for immune drug | ||
| 29.09. | Softgel and lipid-based formulations: An opportunity to optimize performance for challenging therapeutics | ||
| 26.09. | Key exemptions could limit impact of Trump's pharmaceutical tariffs | ||
| 26.09. | Crinetics drug to challenge pharma 'Goliaths'; FDA, ARPA move to speed gene therapies |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .